Insights

Diverse Therapeutic Portfolio Cullinan Therapeutics maintains a diversified pipeline of clinical-stage assets targeting oncology and autoimmune diseases, presenting multiple opportunities for partnerships, licensing, or co-development in high-demand therapeutic areas.

Strong Industry Engagement Regular participation in major industry conferences such as ASCO, ASH, and immunology forums indicates active engagement with key stakeholders and investors, suggesting openings for collaboration, strategic partnerships, and sponsorship opportunities.

Recent Collaborations The licensing deal for velinotamig and partnerships with companies like Genrixbio demonstrate a focus on expanding technology and product offerings, providing avenues for joint ventures, licensing agreements, and technology licensing deals.

Financial Position With revenues between $50 million and $100 million, Cullinan has a solid financial foundation that supports further clinical development, strategic expansions, and potential acquisitions, making it an attractive partner for investors and collaborators.

Innovative Immunology Focus Cullinan’s emphasis on modality-agnostic targeted therapies and immune system harnessing positions it within a cutting-edge segment of biotech, creating opportunities for sales of specialized research tools, licensing of novel therapies, or strategic alliances targeting immune-related indications.

Cullinan Therapeutics Tech Stack

Cullinan Therapeutics uses 8 technology products and services including Level Access, Amazon Web Services, Workato, and more. Explore Cullinan Therapeutics's tech stack below.

  • Level Access
    Accessibility
  • Amazon Web Services
    Cloud Hosting
  • Workato
    Data Integration
  • Font Awesome
    Font Scripts
  • Slick
    Javascript Libraries
  • Adobe Acrobat DC
    Rich Text Editors
  • Adobe Creative Suite
    Visualisation Software
  • Atlassian Confluence
    Wikis

Media & News

Cullinan Therapeutics's Email Address Formats

Cullinan Therapeutics uses at least 2 format(s):
Cullinan Therapeutics Email FormatsExamplePercentage
FLast@cullinanoncology.comJDoe@cullinanoncology.com
92%
Last@cullinanoncology.comDoe@cullinanoncology.com
5%
FMiddleLast@cullinanoncology.comJMichaelDoe@cullinanoncology.com
1%
First.Last@cullinanoncology.comJohn.Doe@cullinanoncology.com
1%
F.Last@cullinanoncology.comJ.Doe@cullinanoncology.com
1%

Frequently Asked Questions

What is Cullinan Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Cullinan Therapeutics is a publicly traded company; the company's stock symbol is CGEM.

What is Cullinan Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Cullinan Therapeutics's official website is cullinantherapeutics.com and has social profiles on LinkedIn.

What is Cullinan Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Cullinan Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cullinan Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, Cullinan Therapeutics has approximately 137 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Ceo: O. H.Chief Medical Officer: J. J.Chief Technical Operations Officer: K. J.. Explore Cullinan Therapeutics's employee directory with LeadIQ.

What industry does Cullinan Therapeutics belong to?

Minus sign iconPlus sign icon
Cullinan Therapeutics operates in the Biotechnology Research industry.

What technology does Cullinan Therapeutics use?

Minus sign iconPlus sign icon
Cullinan Therapeutics's tech stack includes Level AccessAmazon Web ServicesWorkatoFont AwesomeSlickAdobe Acrobat DCAdobe Creative SuiteAtlassian Confluence.

What is Cullinan Therapeutics's email format?

Minus sign iconPlus sign icon
Cullinan Therapeutics's email format typically follows the pattern of FLast@cullinanoncology.com. Find more Cullinan Therapeutics email formats with LeadIQ.

Cullinan Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Cullinan Therapeutics is dedicated to creating new standards of care for patients. 
 
We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class.  

Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.

Notice to Job Seekers: Job applicants should be aware of job recruitment, interview and offer scams being perpetrated through the use of the internet and social media platforms. To learn more, visit our Careers page or read Cullinan’s Employment Recruitment Scams Notice here: https://cullinantherapeutics.com/docs/employment-recruitment-scams-notice.pdf

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CGEM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $50M$100M

    Cullinan Therapeutics's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Cullinan Therapeutics's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.